Best Medication for Hypertension with Family History of Coronary Artery Disease

Primary Recommendation: ACE Inhibitor or ARB

ACE inhibitors and ARBs are specifically recommended as first-line therapy for hypertension in patients with coronary artery disease or at high cardiovascular risk, which applies to patients with a strong family history of CAD in relatively young parents, according to the American College of Cardiology and American Diabetes Association guidelines 1, 2, 4
The American Diabetes Association and American Heart Association guidelines explicitly state that ACE inhibitors or ARBs are the preferred initial agents for patients with coronary artery disease, as they have demonstrated superior cardiovascular protection beyond blood pressure lowering alone 1, 4, 3

If blood pressure is ≥160/100 mmHg, initiate combination therapy immediately with an ACE inhibitor or ARB plus either a thiazide-like diuretic or a dihydropyridine calcium channel blocker, as recommended by the European Heart Journal and Diabetes Care 1, 5, 3
Single-pill combination formulations are strongly preferred as they significantly improve medication adherence compared to separate pills, according to the European Heart Journal and Praxis Medical Insights 5, 3

Beta-blockers should be added if the patient develops angina, has a myocardial infarction, or has other compelling indications, but they are not recommended as first-line monotherapy for uncomplicated hypertension, as stated by the American College of Cardiology and Circulation 4, 2
The 2015 AHA/ACC/ASH Scientific Statement specifically recommends ACE inhibitors or ARBs as foundational therapy for hypertensive patients with coronary artery disease, with beta-blockers reserved for specific indications like post-MI or angina 4

Target blood pressure should be <130/80 mmHg for patients at high cardiovascular risk, including those with family history of premature CAD, according to the European Heart Journal and Journal of the American College of Cardiology 5, 2
The 2024 ESC guidelines recommend targeting systolic BP of 120-129 mmHg in most adults if well tolerated, which is particularly appropriate for patients at elevated cardiovascular risk 5

Monitor serum creatinine, estimated GFR, and potassium levels at baseline and at least annually when using ACE inhibitors or ARBs, as these agents can cause hyperkalemia and acute kidney injury, particularly in patients with underlying renal dysfunction, as recommended by Diabetes Care 1, 6

Never combine an ACE inhibitor with an ARB, as this increases adverse events without providing additional cardiovascular benefit, according to Diabetes Care and European Heart Journal 1, 6, 5
Do not use beta-blockers as initial monotherapy unless there are specific indications such as angina, prior MI, or heart failure with reduced ejection fraction, as stated by the European Heart Journal and Praxis Medical Insights 5, 3

Concurrent lifestyle interventions are mandatory and include: sodium restriction, weight loss if BMI >25 kg/m², Mediterranean or DASH diet, regular aerobic exercise, smoking cessation, and alcohol limitation, as recommended by the European Heart Journal 5